Medicine and Dentistry
Patient
100%
Therapeutic Procedure
66%
Systemic Lupus Erythematosus
59%
Combination Therapy
45%
Inpatient
40%
Rheumatoid Arthritis
37%
Systemic Scleroderma
29%
Cells
29%
B Cell
27%
Methotrexate
24%
Dermatomyositis
24%
Vasculitis
24%
Systemic Lupus Erythematosus
24%
Tumor Necrosis Factor
24%
Serum
23%
Diseases
19%
Biological Product
18%
Prednisolone
18%
Case Report
18%
Infliximab
17%
Disease Activity
16%
Maintenance Therapy
16%
Glucocorticoid
15%
Interstitial Lung Disease
15%
Immunosuppressive Drug
14%
Spontaneous Remission
14%
TNF Inhibitor
13%
Adverse Event
13%
Cell Differentiation
12%
Cytokine
12%
Lymphoid Cell
12%
Prostacyclin
12%
Autologous Hematopoietic Stem Cell Transplantation
12%
Monocyte
12%
Bone Necrosis
12%
Femoral Head
12%
Bleeding
12%
Retrospective Cohort Study
12%
Post-Hoc Analysis
12%
Clinical Trial
12%
Basophil Cell
12%
Immunoglobulin E
12%
Double Stranded DNA
12%
Synovitis
12%
Nivolumab
12%
ANCA Associated Vasculitis
12%
Stomach Cancer
12%
Edema
12%
Collagen Disease
12%
Satisfaction
11%
Immunology and Microbiology
Systemic Lupus Erythematosus
61%
B Cell
43%
Monocyte
34%
Inflammatory Arthritis
31%
CD226
30%
Cells
26%
Dermatomyositis
24%
Methotrexate
24%
Progranulin
24%
Cytotoxic T-Cell
24%
Immunoglobulin G4 Related Disease
20%
Systemic Scleroderma
17%
Lung
16%
Infliximab
15%
Cell Differentiation
12%
Regulatory Cell
12%
Innate Lymphoid Cell
12%
Caspase 1
12%
Pregnancy
12%
Vasculitis
12%
Immunoglobulin E
12%
Basophil Granulocyte
12%
Rheumatic Disease
12%
Mycophenolate Mofetil
12%
CXCL9
9%
Autoantibodies
9%
Th1 Cell
9%
Cell Adhesion Molecule
9%
Carcinoembryonic Antigen
9%
Joint
9%
Human Leukocyte Antigen
8%
Abatacept
8%
Seroconversion
8%
Antibody Response
8%
TNF Inhibitor
8%
Apoptosis
8%
Lupus Erythematosus
7%
Development
7%
Association
7%
Synovial Fluid
6%
Giant Cell Arteritis
6%
Real-Time Polymerase Chain Reaction
6%
T-Helper Cell
6%
Autoimmune Disease
6%
Disease-Modifying Antirheumatic Drug
6%
Macrophage
6%
Uveitis
5%
Immunoglobulin G4
5%
Biological Product
5%
Monospecific Antibody
5%
Pharmacology, Toxicology and Pharmaceutical Science
Systemic Lupus Erythematosus
31%
Systemic Lupus Erythematosus
24%
Disease Activity
23%
Adverse Event
20%
Immunosuppressive Agent
19%
Prognosis
16%
Drug
15%
Infliximab
15%
Immunosuppressive Agent
14%
Cohort Study
13%
Diseases
13%
Mycophenolate Mofetil
12%
Mizoribine
12%
Methotrexate
12%
Edema
12%
Tocilizumab
12%
Hydroxychloroquine
12%
Synovitis
12%
Nivolumab
12%
Progranulin
12%
Dermatomyositis
12%
Myelodysplastic Syndrome
12%
Rheumatic Disease
12%
Stomach Cancer
12%
Tacrolimus
12%
Connective Tissue Disease
12%
Collagen Disease
12%
Lupus Vulgaris
12%
Tumor Necrosis Factor Inhibitor
10%
Hemoglobin A1c
10%
Interstitial Lung Disease
10%
Biological Product
10%
Prednisolone
8%
Rituximab
7%
Rheumatoid Arthritis
7%
Incidence
6%
Syndrome
6%
Mizoribine
6%
Abatacept
6%
Uveitis
5%